Sub Subramony, M.D., discusses how the progression of patients' conditions often leads to a decline in quality of life and functional capabilities, highlighting key clinical indicators that necessitate the adoption of mobility aids.
Video content above is prompted by the following:
Can you shed light on the trajectory of patients’ quality of life, functional capabilities, and overall well-being as the condition advances, and how do you typically discern indications in clinical settings that signal a decline in ambulation necessitating the adoption of mobility aids?
New Model Predicts Stroke Severity and Improves Functional Independence
January 30th 2025A new predictive model developed by Ochsner Health helps clinicians make real-time decisions for patients who had a stroke undergoing urgent carotid intervention, improving chances of regaining functional independence.
Read More
FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease
January 27th 2025The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing while preserving clinical and biomarker benefits.
Read More